Anthraquinone-based intercalating compounds, namely doxorubicin and mitoxantrone, have been used clinically based on their capacity to bind DNA and induce DNA damage. However, their applications have been limited by side effects and drug resistance. New-generation anthraquinone derivatives fused with different heterocycles have been chemically synthesized and screened for higher anticancer potency. Among the
基于
蒽醌的嵌入化合物,即
阿霉素和米托
蒽醌,基于它们结合 DNA 和诱导 DNA 损伤的能力,已在临床上使用。然而,它们的应用受到副作用和耐药性的限制。已经
化学合成了与不同杂环稠合的新一代
蒽醌衍
生物,并筛选了更高的抗癌效力。在我们之前的研究中报道的化合物中,发现 4,11-双(2-(
2-氯乙脒)乙基
氨基)
蒽[2,3-b]
噻吩-5,10-二酮二盐酸盐(命名为 2c)具有凋亡作用,但是导致细胞毒性的直接细胞靶点仍然未知。在这里,我们报告了另外两种衍
生物 4,11-bis(2-(2-chloroacetamidine)ethylamino)naphtho[2,3-f]indole-5,10-dione dihydrochloride (2a) 和 4 , 11-双(2-(
2-氯乙脒)乙基
氨基)-
2-甲基蒽[2,3-b]
呋喃-5,10-二酮二盐酸盐(2b)。我们试图使用分子对接模拟和细胞热位移分析 (CE
TSA)